Pathogen-Reduced Platelet Concentrates: Experience in Routine Practice in Germany
This study, called INITIATE, is happening in Germany and focuses on a new way to make blood platelet transfusions safer. Platelets are important for stopping bleeding, but sometimes they can carry germs. This study looks at 'pathogen-reduced' platelets, where germs are removed to lower risks. Researchers want to see how this new method affects the entire process, from preparing the platelets to using them in hospitals. They are especially interested in whether these new platelets are safe and work well for patients needing transfusions. They're also comparing this new approach to older methods to understand its overall impact on patient care and the healthcare system.
At a glance
What is this study about?
This study is about making blood platelet transfusions safer for patients. Platelets are very important parts of your blood that help it clot and stop bleeding. Sometimes, patients need platelet transfusions, for example, if they have certain conditions that prevent their body from making enough platelets.
Even though blood products are much safer now than they used to be, there's still a tiny risk of transferring germs (like bacteria) with a platelet transfusion. To make them even safer, new methods have been developed to remove or reduce these germs from the platelet concentrates before they are given to patients. This study wants to see how these 'pathogen-reduced' platelets are working in real hospitals and clinics in Germany. Researchers are looking at everything from how these special platelets are prepared and transported, to how safe and effective they are for patients receiving them.
They're comparing this new method to older ways of preparing platelets to understand if it makes a difference to patients' safety and how well the treatment works. The main goal is to gather more information about these new, safer platelet transfusions and ensure they are helping patients as intended.
Key takeaways
- The study assesses a new, safer type of platelet transfusion.
- It's happening in Germany to gather real-world information.
- You would receive standard treatment, not experimental medicine.
- The main goal is to understand the safety and effectiveness of pathogen-reduced platelets.
- Participation helps improve blood transfusion safety for future patients.
Who may be eligible?
To take part in this study, you must be at least 18 years old. You would also need to be a patient who is planned to receive at least one transfusion of these special 'pathogen-reduced' platelets. This transfusion would be for a bleeding risk linked to having very low numbers of platelets, caused by your body not producing enough of them.
There are certain reasons why someone might not be able to join the study. For example, if you're allergic to specific ingredients used in the pathogen reduction process, or if you have certain existing blood conditions like known allergies to human plasma proteins, or conditions such as immune thrombocytopenia or thrombotic microangiopathy. Also, if you have very rare inherited conditions affecting your platelets, you might not be suitable.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you going to receive a platelet transfusion because you have low platelets?
- Is your low platelet count due to your body not making enough platelets?
- Do you have any known allergies to specific ingredients (like amotosalen HCl or psoralens)?
- Do you have conditions like immune thrombocytopenia or thrombotic microangiopathy?
- Do you have certain rare inherited platelet disorders?
What does participation involve?
This study is a bit different because it's a 'non-interventional' safety study. This means you wouldn't receive new or experimental treatment specifically for the study. Instead, the study observes what happens to patients who are already receiving pathogen-reduced platelet transfusions as part of their routine care. You would likely continue your usual medical appointments and treatments as decided by your doctors. The researchers would collect information about your health and your transfusions. You wouldn't need extra visits or take new medication just for the study. The total duration of your participation would depend on your course of treatment and how long the researchers need to collect the relevant safety and effectiveness data related to your platelet transfusions.
Potential risks and benefits
Locations (1)
- Institut für Klinische Transfusionsmedizin (IKT) und DRK Blutspendedienst Baden-Württemberg-Hessen/ Transfusionsambulanz MVZ DRK-Blutspendedienst Ulm gGmbHVerified postcodeUlm, Germany· Recruiting
Common questions
What are platelet concentrates?
Platelet concentrates are transfusions of platelets, which are tiny blood cells that help your blood clot and stop bleeding.
What does 'pathogen-reduced' mean?
It means the platelets have been treated to remove or reduce germs (like bacteria) to make them safer before being transfused.
Will I have to take new medicine for this study?
No, you wouldn't take any new or experimental medication. The study observes patients receiving standard platelet transfusions as part of their normal care.
Why is this study important?
It helps doctors and scientists understand how well these new, safer platelet transfusions work in real life and ensures they are beneficial for patients.
Can I stop participating in the study if I change my mind?
Yes, you can choose to stop participating at any time without it affecting your medical care.
How to find out more
Simone Hoffmann, Dr. rer. nat.
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.